Beyond height: key outcomes in achondroplasia management

Melita Irving

Consultant in Clinical Genetics

Guy's and St Thomas' NHS Trust, London



Disclosures

 Receives honoraria from BioMarin, QED, Ascendis, Novo Nordisk, Sanofi



Complications as a consequence of the secondary abnormal bone formation requiring multidisciplinary care











Box 2 Complications of achondroplasia (%) in childhood

- Neurological
 - Foramen magnum compression (5–10%)
 - Craniocervical instability (very rare)
 - Symptomatic hydrocephalus (6%)
- Orthopaedic
 - Progressive, unresolving thoracolumbar kyphosis
 - Decreased range of movement, elbows and hips
 - Tibial bowing (10%)
 - Symptomatic lumbar spinal stenosis (20%)
- ► ENT
 - Recurrent otitis media (89%)
 - Adenotonsillar hypertrophy (25%)
- Dental
 - Dental overcrowding (>50%)
- Respiratory
 - Sleep apnoea (75%)
- Growth
 - Short stature
 - Increased body mass index
- Development
 - Comparative motor delay
 - Speech delay (25%)
 - Conductive hearing loss (40%)
- Activities of daily living
 - Restricted through short stature, rhizomelic shortening of upper limbs
- Pyschosocial impact for child and family

Medical and surgical burden of Ach: natural history studies



PROPEL Study - QED

Results

- A total of 86 children with ACH enrolled as of January 2022 at 19 sites in Europe, Australia and North America have been included.
- Of the 86 subjects enrolled, 73 (84.9%) had molecular confirmation of their diagnosis.
- Overall, 79.1% of cases (n=68) were sporadic, whereas 11.6% (n=10) had another family member with diagnosis of ACH. Baseline characteristics are summarized in Table 2.
- The most common conditions reported in the medical histories of subjects are summarized in Table 3.

Table 2. Baseline patient characteristics

Characteristic	Total (n=86)
Age, years Mean (SD) Median (range)	6.1 (2.5) 6.2 (2.5–10.8)
Age group, n (%) <3 years 3 to <5 years 5 to <8 years ≥8 years	12 (14.0) 22 (25.6) 26 (30.2) 26 (30.2)
Sex , n (%) Male Female	34 (39.5) 52 (60.5)
Race, n (%) White Asian Black or African American Other Not reported	54 (62.8) 8 (9.3) 4 (4.7) 7 (8.1) 13 (15.1)

Characteristic	Number of subjects (%)
Surgical and medical procedures	58 (67.4)
Infections and infestations	46 (53.5)
Respiratory, thoracic, and mediastinal disorders	40 (46.5)
Musculoskeletal and connective tissue disorders	33 (38.4)
Congenital, familial, and genetic disorders	31 (36.0)
Nervous system disorders	16 (18.6)
Ear and labyrinth disorder	15 (17.4)

Characteristic	Number of subjects (%)*
Adenoidectomy/adenotonsillectomy/tonsillectomy	34 (39.5)
Spinal and cranial surgeries	21 (24.4)
Decompressive craniectomy	14 (16.3)
Spinal decompression	5 (5.8)
Spinal laminectomy	3 (3.5)
Foraminotomy	1 (1.2)
Spinal fusion surgery	1 (1.2)
Spinal operation	1 (1.2)
Ear procedures and operations	32 (37.2)
Ear tube insertion	32 (37.2)
Myringotomy	3 (3.5)
Middle ear operation	1 (1.2)
Ear tube removal	1 (1.2)
Orthopedic procedures	6 (7.0)
Device therapy	3 (3.5)
Meniscus operation	1 (1.2)
Orthopedic procedure	1 (1.2)
Osteotomy	1 (1.2)
Rhizolysis	1 (1.2)
Ventriculo-peritoneal shunt	2 (2.3)
Mechanical ventilation	2 (2.3)
Palatal implant	2 (2.3)
Turbinectomy	2 (2.3)

Table 4. Surgical and medical procedures occurring in \geq 1 subject

*Subjects could be counted more than once if they underwent ≥1 procedure

Functionality, independence skills, day-to-day living and health-related quality of life:



Assessment of daily functionality: PEDICAT (n=29, 3-17yo)

DOMAIN	$< 5^{th}\%$	5-25 th %	25-50 th %	50-75 th %	7 5-95 th %	N=
Daily activities	9	12	4	4	1	30
Mobility	21	6	2	0	0	29
Social-cognitive	6	10	5	6	0	27
Responsibility	4	3	4	3	1	15

MG23122013 for Identification Number Daily Activities Item Map Score = 60, SE = 0.68, Fit = -1.44

- 2

1 2

2

3

Ē

- 3

2

3

2

2 2

50

3

4

4

2

3

2 3 4

2

2

22



Holds/eats sand/wich/burs/ Holds/eats sand/wich/burs/ Feeds self with fork Feeds self with spoon Holds/drinks from open cup/glass Drinks liquids using straw Finger feeds Swallows purced/ blended/ strained foods

20

30

1 = Unable, 2 = Hard, 3 = A little hard, 4 = Easy

40

60

HRQOL tools and height Z-score

PedsQL and height Z-score



UL Ratios by Age Subgroups Over Time



Age Group, n	Baseline	6 Months	12 Months	18 Months
≤1	15	13	9	6
>1-2	23	18	11	6
>2-5	61	47	21	8
>5	52	36	20	9

Participants are arranged in sub-groups by age at enrollment into the ACHieve study. UL ratio, upper to lower body proportion ratio.

All product candidates are investigational. Intended for education and scientific exchange only. Not for use in promotion or product commercialization

Trend towards improvement in upper to lower body segment ratio after 2 years



1. Savarirayan R et al. Lancet 2020;396:684-92;

2. Savarirayan R et al. Genet Med 2021;doi:10.1038/s41436-021-01287-7

Baseline defined as time of initiation of vosoritide treatment

Foramen magnum stenosis



Achondroplasia Foramen Magnum Score: screening infants for stenosis

Moira S Cheung ^(D), ¹ Melita Irving, ² Alessandra Cocca ^(D), ¹ Rui Santos, ³ Meera Shaunak, ¹ Harry Dougherty, ¹ Ata Siddiqui, ⁴ Paul Gringras, ⁵ Dominic Thompson⁶

Cheung MS, et al. Arch Dis Child 2021;106:180-184.

Ach foramen magnum stenosis score (AFMSS)

AFMS0	AFMS1	AFM52	AFM53	AFM54
Normal foramen magnum	Constitutional narrowing of the foramen magnum with preserved CSF (no cord distortion)	Narrowing of the foramen magnum with loss of CSF space surrounding the cord	Loss of the CSF space with cord compression	Cord compression and signal changes (Myelomalacia)
	3	Y		

Table 1 Baseline characteristic	s of patients
Characteristic	Number of infants (n=36)
Gender	
Male	18 (50%)
Female	18 (50%)
Timing of diagnosis	
Antenatal period	23 (64%)
Postnatal period	12 (33%)
Unknown	1 (3%)
Diagnostic investigations	
Genetic testing (FGFR3)	33 (92%)
Skeletal survey only	3 (8%)



Sleep-disordered breathing



Incidence of sleep disordered breathing

- 61.1% (22) reported snoring and/or sleep apnoea
- Cardiorespiratory sleep studies performed on 35 infants
- Sleep disordered breathing detected in 88.5% (31/35)
 - Mild obstructive sleep apnoea (OSA) in 11.4% (4)
 - Mod OSA in 11.4% (4)
 - Severe OSA in 43.8% (12)

Sleep disordered breathing n=81 Achondroplasia



Across the life course:



Pain in Ach





Pain

- Alade *et al.* 2013:
 - 316 with short stature skeletal dysplasia
 - 153 with Ach
 - Chronic pain prevalence (brief pain inventory): 70.3%
 - 63.1% in Ach group

Weight management in Ach



Obesity

- 50% in Ach abdominal
- Without typical secondary complications (normoglycaemia)
- Worsens overall clinical status



Saint-Laurent et al. 2018

Mental Health



Higher rates of non-skeletal complications in achondroplasia compared to the general population: A UK matched cohort study using the CPRD-GOLD database

Melita Irving, Jeanne M. Pimenta, Moira Cheung, Louise Mazzeo, Sarah Landis, Swati Mukhergee

Matched retrospective cohort study using UK Clinical Practice Research Datalink (CPRD-GOLD)

■ Study index date was first ACH record within study period of 01/01/1987–31/12/2018

■ Control patients defined as those without evidence of skeletal/growth disorders

We identified 541 cases and 2,052 matched controls

	Pate Patio	Specific Statistically significantly higher RR in ACH compared to controls		omplications	
Body system	RR (95% Cls)			No difference in RR between ACH cases and controls	Condition included in body system but <5 events ¹
Any Non-skeletal	1.76 (1.56–1.98)				
Developmental	8.84 (4.18–18.72)	Developmental delay Speech delay	8.80 (3.02–25.68) 7.61 (3.03–19.13)	_	Motor delay
Neurological	7.56 (4.24–13.50)	Seizures Hydrocephalus/ ventriculomegaly	4.01 (1.52–10.58) Cases only	Dementia	Craniocervical stenosis Failure to thrive Subdural haematoma
Respiratory	4.15 (2.51–6.88)	Apnoea/sleep disordered breathing	25.81 (10.0–66.60)	Sleep disorder	-
ENT	2.98 (2.43–3.65)	Enlarged tonsils Hearing loss/ deafness Otitis media	3.34 (1.26–8.86) 3.50 (2.50–4.89) 3.11 (2.45–3.94)	Sinusitis Voice abnormality	Middle ear dysfunction Tracheomalacia Bronchomalacia
Metabolic	1.65 (1.24–2.18)	Obesity	2.59 (2.26–2.97)	Diabetes Hyperlipidaemia	-
Mental Health	1.62 (1.21–2.17)	ADD/ADHD/ adjustment disorder Depression/anxiety Self-harm/suicidal ideation	3.44 (1.13–10.51) 1.51 (1.09–2.08) 3.71 (1.17–11.77)	Substance abuse	'Other' mental health
Cardiovascular	1.17 (0.92–1.49)	_		Chest pain/angina Coronary disease Hypertension Myocardial infarction Stroke	_
Other	1.76 (1.52–2.03)	Gastrointestinal issues Pain-musculoskeletal	1.66 (1.31–2.09) 1.84 (1.58–2.15)	Headache Sexual health/ gynaecological issues	-

¹Due to database requirements, data for cases or controls which have less than 5 events are not permitted to be reported.

Summary – benefits beyond height wish-list:

- Reduced medical and surgical burden
- Improved functionality and independence skills
- No sleep disordered breathing or foramen magnum stenosis.....
- Benefits lasting into adulthood:
 - Pain
 - Obesity
 - Spinal stenosis
 - Mental health

Thanks for listening





European Achondroplasia Forum